STOCK TITAN

Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.

Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.

Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.

For more information, please visit www.karyopharm.com.

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the commercial availability of three new strength tablets for XPOVIO, following FDA approval on April 15, 2021. The new strengths of 40 mg, 50 mg, and 60 mg supplement the existing 20 mg tablet, enhancing patient compliance and treatment flexibility. XPOVIO is a first-in-class oral Selective Inhibitor of Nuclear Export (SINE) approved for multiple myeloma and diffuse large B-cell lymphoma. The new strengths do not alter the drug's efficacy or safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 2, 2021, that the UK's Medicines & Healthcare Products Regulatory Agency granted conditional marketing authorization for NEXPOVIO® (selinexor) in combination with dexamethasone to treat multiple myeloma in adult patients who have undergone at least four prior therapies. This authorization is based on positive results from the Phase 2b STORM study, which reported a 26% overall response rate in heavily pretreated patients. Continued authorization will depend on confirming clinical benefits in further trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 1, 2021, the grant of stock options totaling 24,600 shares to six newly-hired employees as an inducement related to their employment. The options were granted at an exercise price of $9.28 per share, equal to KPTI's closing stock price on May 28, 2021. Each option will vest over four years, with the first 25% vesting on the one-year anniversary of employment. If a 'change in control event' occurs, options may become immediately exercisable upon certain termination conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
Rhea-AI Summary

On May 26, 2021, Karyopharm Therapeutics (Nasdaq: KPTI) announced that CEO Richard Paulson will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference. The event is scheduled for June 2, 2021, at 9:30 a.m. ET. A live webcast can be accessed through the Investor section of the company's website, with a replay available for 30 days post-event. Karyopharm focuses on pioneering novel cancer therapies, including its lead compound XPOVIO® (selinexor), approved for multiple hematologic malignancies in the U.S. and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the selection of sixteen abstracts for virtual presentation at the ASCO Annual Meeting from June 4-8, 2021. Key highlights include clinical data on XPOVIO® (selinexor) from pivotal studies, showcasing its efficacy in treating multiple myeloma and other cancers. The presentations feature subgroup analyses from the Phase 3 BOSTON study and updates from various combination studies, emphasizing the potential of XPOVIO in overcoming treatment resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 55,300 shares to seven new employees as an inducement for joining the company. The options have an exercise price of $9.34, based on the stock's closing price on April 30, 2021. Each option vests over four years, with the first 25% vesting after one year. These options may be fully exercised if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event. Karyopharm focuses on developing novel cancer therapies, including its lead drug, XPOVIO®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.17%
Tags
none
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) reported first-quarter 2021 results, showing a net product revenue of $21.7 million, up 35% year-over-year. The company highlighted a leadership transition with Richard Paulson appointed as the new CEO. The ongoing U.S. commercialization of XPOVIO reflects a significant increase in prescription demand, with approximately 1,170 prescriptions filled, marking a 17% increase from Q4 2020. Karyopharm anticipates top-line data from the Phase 3 SIENDO study by year-end and expects a decision from the European Commission on NEXPOVIO in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
-
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) appointed Richard Paulson as President and Chief Executive Officer effective May 3, 2021, succeeding Michael G. Kauffman and Sharon Shacham. Paulson, who has extensive biopharmaceutical experience and previously served as CEO of Ipsen North America, aims to enhance Karyopharm's commercialization efforts and expand the reach of its lead product, XPOVIO. Kauffman transitions to Senior Clinical Advisor, focusing on clinical developments. The leadership change is positioned as essential for driving growth and innovation at a pivotal moment for the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
management
-
Rhea-AI Summary

Karyopharm Therapeutics (NASDAQ:KPTI) will report its first quarter 2021 financial results on May 3, 2021. The company's management will host a conference call at 8:30 a.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead compound, XPOVIO (selinexor), which is approved for multiple indications and has received conditional marketing authorization in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences earnings
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) has announced the validation of its Type II Variation Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for NEXPOVIO® (selinexor). This application aims to expand the use of NEXPOVIO in combination with Velcade® and low-dose dexamethasone for treating adult patients with multiple myeloma who have undergone at least one prior therapy. The decision is based on encouraging results from the Phase 3 BOSTON study. The EMA's review is expected to conclude in Q4 2021, signifying a vital step in enhancing treatment options for multiple myeloma in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none

FAQ

What is the current stock price of Karyopharm Therapeutics (KPTI)?

The current stock price of Karyopharm Therapeutics (KPTI) is $0.635 as of December 20, 2024.

What is the market cap of Karyopharm Therapeutics (KPTI)?

The market cap of Karyopharm Therapeutics (KPTI) is approximately 82.5M.

What is Karyopharm Therapeutics' main focus?

Karyopharm Therapeutics specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other major diseases.

What is XPOVIO® (selinexor)?

XPOVIO® is a first-in-class, oral exportin 1 (XPO1) inhibitor approved for the treatment of multiple oncology indications, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL).

What recent achievements has Karyopharm reported?

Karyopharm recently announced promising long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib for myelofibrosis. The company also reported strong financial performance with total revenue of $146.0 million for the year 2023.

Who are Karyopharm's global partners?

Karyopharm has partnered with Antengene, Menarini, Neopharm, and FORUS to market XPOVIO in international markets, including Europe, China, South Korea, and Israel.

What are Karyopharm's financial highlights?

For Q4 2023, Karyopharm reported total revenue of $33.7 million and a full-year revenue of $146.0 million. The company had a cash position of $192.4 million as of December 31, 2023.

What are the key indications for XPOVIO?

XPOVIO is approved for use in combination with Velcade and dexamethasone for multiple myeloma, in combination with dexamethasone for heavily pre-treated multiple myeloma, and as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

What is the significance of Karyopharm's research on nuclear export proteins?

Karyopharm's research targets nuclear export dysregulation, a fundamental mechanism of oncogenesis, aiming to develop therapies that inhibit this process and treat various cancers effectively.

How does Karyopharm support clinical trials and research?

Karyopharm is engaged in several mid- and late-stage clinical trials across multiple high unmet need cancer indications, including endometrial cancer and myelofibrosis. The company also collaborates with global partners and research institutions to advance its pipeline.

What are the safety considerations for XPOVIO?

Common treatment-emergent adverse events for XPOVIO include nausea, vomiting, diarrhea, and neutropenia. Patients are advised not to breastfeed during treatment. Full prescribing information is available on www.XPOVIO.com.

How can I get more information about Karyopharm's products or clinical trials?

For more information, you can contact Karyopharm's Medical Information department at +1 (888) 209-9326 or via email at medicalinformation@karyopharm.com.

Karyopharm Therapeutics Inc.

Nasdaq:KPTI

KPTI Rankings

KPTI Stock Data

82.52M
117.36M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON